Outsourcing: Analysis and developments of contract service providers to the pharmaceutical and biotechnology industries - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outsourcing
Contract manufacturing organizations (CMOs) and contract research organizations (CROs). Global sourcing of pharma ingredients and services. Trends and challenges for the biopharmaceutical and pharmaceutical industries.

Report from Poland

May 2, 2012

Pharmaceutical Technology

Poland's government aims to make the Eastern European country a biotech powerhouse.

Bioprocessing Trends: Annual Survey Results

May 1, 2012

Pharmaceutical Technology

Readers share their views on bioprocessing challenges, equipment use, and outsourcing trends in our annual bioprocessing equipment and processing survey.

Inside INFORMEX: Evaluating the Market for Contract API Manufacturing

April 2, 2012

Pharmaceutical Technology

Contract API manufacturers and fine-chemical producers roll out capacity and service expansions.

Q&A with Erik van den Berg, AM-Pharma

April 2, 2012
Pharmaceutical Technology

A Q&A with Erik van den Berg, CEO of AM-Pharma, on recent industry trends.

Ways to Recover Lost Margins

April 2, 2012

Pharmaceutical Technology

Recovery audits and other past practices in procurement can improve the bottom line.

A Look at INTERPHEX 2012

April 2, 2012

Pharmaceutical Technology

Collaboration can begin with a conversation.

Report from China

April 2, 2012

Pharmaceutical Technology

China's drug-distribution network has been a mess for years, but government reforms and industry focus are unveiling new opportunities for market order and growth.

CMOs Face a Kodak Moment

March 2, 2012

Pharmaceutical Technology

The evolving bio/pharmaceutical business model poses risk for CMOs.

Report from Brazil

March 2, 2012

Pharmaceutical Technology

Brazil's generic-drug market is growing steadily.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here